Paroxetine: Population pharmacokinetic analysis in late-life depression using sparse concentration sampling

British Journal of Clinical Pharmacology

Volumn 61, Issue 5, 2006, Pages 558-569

  Feng, Yan ^a   Pollock, Bruce G ^b,c   Ferrell, Robert E ^d   Kimak, Mark A ^d   Reynolds III, Charles F ^c   Bies, Robert R ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CYP2D6 polymorphism; Geriatrics; NONMEM; Paroxetine; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2D6; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

AGE; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENOTYPE; GERIATRICS; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MICHAELIS MENTEN KINETICS; NONLINEAR SYSTEM; PHARMACOKINETIC MODEL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE DIFFERENCE; SAMPLING; SEX DIFFERENCE;

AGE FACTORS; AGED; BODY WEIGHT; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; MALE; NONLINEAR DYNAMICS; PAROXETINE; POLYMERASE CHAIN REACTION; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 33646271839     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02629.x     Document Type: Article

References (41)

1. Wagstaff AJ Cheer SM Matheson AJ Ormrod D Goa KL Paroxetine: an update of its use in psychiatric disorders in adults Drugs 2002 62 655 703
2. Pollock BG Ferrell RE Mulsant BH Mazumdar S Miller M Sweet RA Davis S Kirshner MA Houck PR Stack JA Reynolds CF Kupfer DJ Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression Neuropsychopharmacology 2000 23 587 90
3. Reis M Lundmark J Bengtsson F Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997 Ther Drug Monit 2003 25 183 91
4. Feng Y Pollock B Roose S Kirshner M Lotrich F Kupfer D Bies R Mixed effects pharmacokinetic modeling of an age effect on citalopram disposition AAPS Pharmsci 2003 5 Abstract M1063
5. Kaye CM Haddock RE Langley PF Mellows G Tasker TC Zussman BD Greb WH A review of the metabolism and pharmacokinetics of paroxetine in man Acta Psychiatr Scand Suppl 1989 350 60 75
6. Bies RR Feng Y Lotrich FE Kirshner MA Roose S Kupfer DJ Pollock BG Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects J Clin Pharmacol 2004 44 1352 9
7. Walters G Reynolds CF3rd Mulsant BH Pollock BG Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years J Clin Psychiatry 1999 60 Suppl. 20 21 5
8. Meijer WE Bouvy ML Heerdink ER Urquhart J Leufkens HG Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors Br J Psychiatry 2001 179 519 22
9. Henry ME Moore CM Kaufman MJ Michelson D Schmidt ME Stoddard E Vuckevic AJ Berreira PJ Cohen BM Renshaw PF Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study Am J Psychiatry 2000 157 1506 8
10. Findling RL Reed MD Myers C O'Riordan MA Fiala S Branicky L Waldorf B Blumer JL Paroxetine pharmacokinetics in depressed children and adolescents J Am Acad Child Adolesc Psychiatry 1999 38 952 9
11. Sindrup SH Brosen K Gram LF Hallas J Skjelbo E Allen A Allen GD Cooper SM Mellows G Tasker TC The relationship between paroxetine and the sparteine oxidation polymorphism Clin Pharmacol Ther 1992 51 278 87
12. Sindrup SH Brosen K Gram LF Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism Clin Pharmacol Ther 1992 51 288 95
13. Sawamura K Suzuki Y Someya T Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine Eur J Clin Pharmacol 2004 60 553 7
14. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. (last accessed: 30 September 2005).
15. Kagimoto M Heim M Kagimoto K Zeugin T Meyer UA Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes J Biol Chem 1990 265 17209 14
16. Bradford LD CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 2002 3 229 43
17. Ozdemir V Tyndale RF Reed K Herrmann N Sellers EM Kalow W Naranjo CA Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers J Clin Psychopharmacol 1999 19 472 5
18. Aarons L Population pharmacokinetics: theory and practice Br J Clin Pharmacol 1991 32 669 70
19. Thomas L Mulsant BH Solano FX Black AM Bensasi S Flynn T Harman JS Rollman BL Post EP Pollock BJ Reynolds CF III Response speed and rate of remission in primary and specialty care of elderly patients with depression Am J Geriatr Psychiatry 2002 10 583 91
20. Foglia JP Sorisio D Kirshner M Pollock BG Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection J Chromatogr B Biomed Sci Appl 1997 693 147 51
21. Bartlett J White A PCR Protocols 2nd edn Totowa, NJ: Humana Press 2003
22. Higuchi R PCR TechnologyPrinciples and Applications for DNA Amplification 2nd edn New York Oxford University Press 1992
23. Lundqvist E Johansson I Ingelman-Sundberg M Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes Gene 1999 226 327 38
24. Cheng S Fockler C Barnes WM Higuchi R Effective amplification of long targets from cloned inserts and human genomic DNA Proc Natl Acad Sci USA 1994 91 5695 9
25. Steen VM Andreassen OA Daly AK Tefre T Borresen AL Idle JR Gulbrandsen AK Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology Pharmacogenetics 1995 5 215 23
26. Wan YJ Poland RE Han G Konishi T Zheng YP Berman N Lin KM Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California Pharmacogenetics 2001 11 489 99
27. Mendoza R Wan YJ Poland RE Smith M Zheng Y Berman N Lin KM CYP2D6 polymorphism in a Mexican American population Clin Pharmacol Ther 2001 70 552 60
28. Masimirembwa C Persson I Bertilsson L Hasler J Ingelman-Sundberg M A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity Br J Clin Pharmacol 1996 42 713 9
29. Raimundo S Toscano C Klein K Fischer J Griese EU Eichelbaum M Schwab M Zanger UM A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects Clin Pharmacol Ther 2004 76 128 38
30. Rau T Heide R Bergmann K Wuttke H Werner U Feifel N Eschenhagen T Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment Pharmacogenetics 2002 12 465 72
31. Sheiner LB Rosenberg B Marathe VV Estimation of population characteristics of pharmacokinetic parameters from routine clinical data J Pharmacokinet Biopharm 1977 5 445 79
32. Beal B Sheiner L NONMEM User's Guide Part I. San Francisco University of California at San Francisco 1992
33. Ette EI Ludden TM Population pharmacokinetic modeling: the importance of informative graphics Pharm Res 1995 12 1845 55
34. Wennerholm A Johansson I Massele AY Lande M Alm C Aden-Abdi Y Dahl ML Ingelman-Sundberg M Bertilsson L Gustafsson LL Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype Pharmacogenetics 1999 9 707 14
35. Akaike H A new look at the statistical model indentification IEEE Trans Automat Control 1974 AC 19 716 23
36. Preskorn S Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline Int Clin Psychopharmacol Supplement 1994 3 13 9
37. Bertilsson L Dahl M Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders CNS Drugs 1996 5 200 23
38. Cornish-Bowden A Fundamentals of Enzyme Kinetics London Portland Press 1995
39. Cornish-Bowden A Analysis of Enzyme Kinetic Data Oxford, New York Oxford University Press 1995
40. Feng Y Pollock B Reynolds C Bies R Paroxetine pharmacokinetics in geriatric patients AAPS PharmSci 2004 Abstract M1116
41. Wennerholm A Dandara C Sayi J Svensson JO Abdi YA Ingelman-Sundberg M Bertilsson L Hasler J Gustafsson LL The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity Clin Pharmacol Ther 2002 71 77 88